Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465567 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
A Phase 3 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,588
- Enrollment target
NCT02465567 is a Phase 3 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 8,588 participants.
The verdict
NCT02465567, a Phase 3 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,588 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
Interventions
- DRUG BGF MDI 320/14.4/9.6 μg
- DRUG GFF MDI 14.4/9.6 μg
- DRUG BFF MDI 320/9.6 μg
- DRUG BGF MDI 160/14.4/9.6 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,588 participants |
| Start Date | 2015-06-30 |
| Est. Completion | 2019-07-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465567
The ClinicalTrials.gov registry entry for NCT02465567 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,588 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BGF MDI 320/14.4/9.6 μg is the first listed.
NCT02465567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465567 about?
NCT02465567 is a clinical study titled "Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)". This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
What is the current status of trial NCT02465567?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,588 participants. The study started on 2015-06-30. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT02465567?
The interventions under investigation include: BGF MDI 320/14.4/9.6 μg (DRUG), GFF MDI 14.4/9.6 μg (DRUG), BFF MDI 320/9.6 μg (DRUG), BGF MDI 160/14.4/9.6 μg (DRUG).
Who is sponsoring clinical trial NCT02465567?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.